<?xml version='1.0' encoding='utf-8'?>
<document id="26514315"><sentence text="Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies."><entity charOffset="11-23" id="DDI-PubMed.26514315.s1.e0" text="Fostamatinib" /><entity charOffset="51-58" id="DDI-PubMed.26514315.s1.e1" text="Digoxin" /><pair ddi="false" e1="DDI-PubMed.26514315.s1.e0" e2="DDI-PubMed.26514315.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s1.e0" e2="DDI-PubMed.26514315.s1.e1" /></sentence><sentence text="Fostamatinib, a spleen tyrosine kinase inhibitor and prodrug of the active metabolite R406, is being developed as an anti-inflammatory drug for several indications for which polypharmacy is likely"><entity charOffset="0-12" id="DDI-PubMed.26514315.s2.e0" text="Fostamatinib" /><entity charOffset="23-31" id="DDI-PubMed.26514315.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.26514315.s2.e0" e2="DDI-PubMed.26514315.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s2.e0" e2="DDI-PubMed.26514315.s2.e1" /></sentence><sentence text=" Digoxin, indicated for congestive cardiac failure, may be used for certain supraventricular dysrhythmias"><entity charOffset="1-8" id="DDI-PubMed.26514315.s3.e0" text="Digoxin" /></sentence><sentence text=" The studies reported herein examined whether fostamatinib and R406 are inhibitors of P-glycoprotein (P-gp) in vitro and evaluated the effect of fostamatinib on the pharmacokinetic parameters of digoxin to understand drug-drug interaction (DDI) potential in the clinic"><entity charOffset="46-58" id="DDI-PubMed.26514315.s4.e0" text="fostamatinib" /><entity charOffset="145-157" id="DDI-PubMed.26514315.s4.e1" text="fostamatinib" /><entity charOffset="195-202" id="DDI-PubMed.26514315.s4.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.26514315.s4.e0" e2="DDI-PubMed.26514315.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s4.e0" e2="DDI-PubMed.26514315.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26514315.s4.e0" e2="DDI-PubMed.26514315.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26514315.s4.e1" e2="DDI-PubMed.26514315.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26514315.s4.e1" e2="DDI-PubMed.26514315.s4.e2" /></sentence><sentence text="" /><sentence text="Inhibition of P-gp-mediated digoxin transport by fostamatinib and R406 was determined across Caco-2 cell monolayers"><entity charOffset="49-61" id="DDI-PubMed.26514315.s6.e0" text="fostamatinib" /></sentence><sentence text=" Apparent permeability of digoxin was determined and used to calculate efflux ratios and percentage inhibition"><entity charOffset="26-33" id="DDI-PubMed.26514315.s7.e0" text="digoxin" /></sentence><sentence text=" Half maximal inhibitory concentrations (IC50) and theoretical gastrointestinal concentration [I2] (dose in moles per 250 mL) were calculated to gauge clinical DDI potential" /><sentence text=" In a subsequent Phase I study, the plasma concentration-time profiles and resulting pharmacokinetic parameters were examined across 2 treatment periods: (1) oral digoxin loading dose of 0"><entity charOffset="163-170" id="DDI-PubMed.26514315.s9.e0" text="digoxin" /></sentence><sentence text="25 mg BID on day 1 and 0" /><sentence text="25 mg once daily on days 2 to 8, and (2) oral digoxin 0"><entity charOffset="46-53" id="DDI-PubMed.26514315.s11.e0" text="digoxin" /></sentence><sentence text="25 mg once daily and oral fostamatinib 100 mg BID on days 9 to 15"><entity charOffset="26-38" id="DDI-PubMed.26514315.s12.e0" text="fostamatinib" /></sentence><sentence text="" /><sentence text="Fostamatinib (but not R406) was determined to be a P-gp inhibitor in vitro (IC50 = 3"><entity charOffset="0-12" id="DDI-PubMed.26514315.s14.e0" text="Fostamatinib" /></sentence><sentence text="2 μM)" /><sentence text=" On the basis of a theoretical gastrointestinal concentration (I2)/IC50 ratio of 216 ([I2] = 691 μM), predictions indicated the potential for absorption-based DDI in vivo through inhibition of intestinal P-gp" /><sentence text=" In the clinical study, when digoxin was co-administered with fostamatinib, digoxin levels were higher before dosing and throughout the dosing interval, and an increase in exposure to digoxin was observed"><entity charOffset="29-36" id="DDI-PubMed.26514315.s17.e0" text="digoxin" /><entity charOffset="62-74" id="DDI-PubMed.26514315.s17.e1" text="fostamatinib" /><entity charOffset="76-83" id="DDI-PubMed.26514315.s17.e2" text="digoxin" /><entity charOffset="184-191" id="DDI-PubMed.26514315.s17.e3" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e0" e2="DDI-PubMed.26514315.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e0" e2="DDI-PubMed.26514315.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e0" e2="DDI-PubMed.26514315.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e0" e2="DDI-PubMed.26514315.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e1" e2="DDI-PubMed.26514315.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e1" e2="DDI-PubMed.26514315.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e1" e2="DDI-PubMed.26514315.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e2" e2="DDI-PubMed.26514315.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26514315.s17.e2" e2="DDI-PubMed.26514315.s17.e3" /></sentence><sentence text=" Co-administration led to a 1" /><sentence text="70-fold increase in digoxin maximum plasma concentration at steady state (Cmax,ss) versus digoxin administration alone (2"><entity charOffset="20-27" id="DDI-PubMed.26514315.s19.e0" text="digoxin" /></sentence><sentence text="18 vs 1" /><sentence text="32 ng/mL)" /><sentence text=" Median digoxin time of Cmax was earlier when digoxin was co-administered with fostamatinib (1"><entity charOffset="8-15" id="DDI-PubMed.26514315.s22.e0" text="digoxin" /><entity charOffset="46-53" id="DDI-PubMed.26514315.s22.e1" text="digoxin" /><entity charOffset="79-91" id="DDI-PubMed.26514315.s22.e2" text="fostamatinib" /><pair ddi="false" e1="DDI-PubMed.26514315.s22.e0" e2="DDI-PubMed.26514315.s22.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s22.e0" e2="DDI-PubMed.26514315.s22.e1" /><pair ddi="false" e1="DDI-PubMed.26514315.s22.e0" e2="DDI-PubMed.26514315.s22.e2" /><pair ddi="false" e1="DDI-PubMed.26514315.s22.e1" e2="DDI-PubMed.26514315.s22.e1" /><pair ddi="false" e1="DDI-PubMed.26514315.s22.e1" e2="DDI-PubMed.26514315.s22.e2" /></sentence><sentence text="00 vs 1" /><sentence text="48 hours)" /><sentence text=" The digoxin AUC during the dosing interval at steady state was increased 1"><entity charOffset="5-12" id="DDI-PubMed.26514315.s25.e0" text="digoxin" /></sentence><sentence text="37-fold with co-administration" /><sentence text=" No severe or serious adverse events or deaths were reported" /><sentence text="" /><sentence text="Fostamatinib was confirmed to be a P-gp inhibitor in vitro and in vivo, and a DDI with digoxin was apparent"><entity charOffset="0-12" id="DDI-PubMed.26514315.s29.e0" text="Fostamatinib" /><entity charOffset="87-94" id="DDI-PubMed.26514315.s29.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.26514315.s29.e0" e2="DDI-PubMed.26514315.s29.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s29.e0" e2="DDI-PubMed.26514315.s29.e1" /></sentence><sentence text=" Co-administration of digoxin and fostamatinib was generally well tolerated"><entity charOffset="22-29" id="DDI-PubMed.26514315.s30.e0" text="digoxin" /><entity charOffset="34-46" id="DDI-PubMed.26514315.s30.e1" text="fostamatinib" /><pair ddi="false" e1="DDI-PubMed.26514315.s30.e0" e2="DDI-PubMed.26514315.s30.e0" /><pair ddi="false" e1="DDI-PubMed.26514315.s30.e0" e2="DDI-PubMed.26514315.s30.e1" /></sentence><sentence text=" However, continued review of digoxin response and dose is advisable should these agents be prescribed concomitantly" /><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01355354" /><sentence text="" /></document>